Please assess the completion status of the following clinical trial:

Trial Title: Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age;~* Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy~* Confirmed T790M mutation~* Progressed on previous EGFR TKI treatment. Patients may have also received additional lines of treatment~* Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016~Exclusion Criteria:~• Enrolment in studies that prohibit any participation in this observational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EGFR T790M Patients (Type: None): Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI

Based on this trial design, predict the completion outcome and termination type (if applicable).